Namaste Home Health and Hospice’s Post

Dysregulation of the complement system is a key driver of neuromyelitis optica spectrum disorder (#NMOSD), a disease that can result in destruction of cells in the optic nerve, spinal cord and brain. In this video, learn more about this #RareDisease and how we are working to follow the science to advance NMOSD care. #AANAM

💡The European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN) is excited to announce the third annual DIN Day that will be marked on 11th June. ✅DIN Day is an international awareness day dedicated to rare neurological diseases known as dysimmune inflammatory neuropathies (DIN). 
 ➡️It is celebrated every year on June the 11th, the date of Alexander the Great’s death. According to recent studies, the Macedonian king would have died from the consequences of a DIN, the Guillain-Barrè Syndrome. #DINDay #NeurologicalAwareness #EPODIN #RareDiseases #GuillainBarréSyndrome https://ow.ly/GXFS50S8sFc

March is Brain Injury Awareness Month. The Pharma Research Services team will be sharing relevant facts throughout the month to raise awareness of the impacts of traumatic brain injury (TBI). Test your knowledge each week to see how much you've learned! #PharmaResearchServices #BrainInjuryAwarenessMonth

Announcing a game changer for patients with mild Traumatic Brain Injury (mTBI) ‼ 📢 VIDAS® TBI (GFAP, UCH-L1)   VIDAS® TBI (GFAP, UCH-L1) safely rules out intracranial lesions (ICL) by simultaneously testing with a combination of biomarkers released in the hours after a #brain trauma.  Its broad window of up to 12 hours covers a wide adult mTBI patient population. Current mTBI patient workup can be subjective and time-consuming. Clinicians typically use CT-scans to rule out ICL.  VIDAS® TBI (GFAP, UCH-L1) raises the standard of care by objectively determining if a CT-scan is needed or not.  🚑 Find out how you can save time & resources while gaining confidence for mTBI patient workup with VIDAS® TBI (GFAP, UCH-L1).  👉 https://lnkd.in/dnX2Tg7Y #WorldHeadInjuryAwarenessDay #WeArebioMérieux

Announcing a game changer for patients with mild Traumatic Brain Injury (mTBI) ‼ 📢 VIDAS® TBI (GFAP, UCH-L1) #VIDAS® TBI (GFAP, UCH-L1) safely rules out intracranial lesions (ICL) by simultaneously testing with a combination of biomarkers released in the hours after a #brain trauma. Its broad window of up to 12 hours covers a wide adult #mTBI patient population. Current mTBI patient workup can be subjective and time-consuming. Clinicians typically use CT-scans to rule out ICL. VIDAS® TBI (GFAP, UCH-L1) raises the standard of care by objectively determining if a CT-scan is needed or not. Find out how you can save time & resources while gaining confidence for mTBI patient workup with VIDAS® TBI (GFAP, UCH-L1) ⬇️ https://bddy.me/3THGMBn #WorldHeadInjuryAwarenessDay

In the June #UOGJournal Spruijt et al. aim to describe the types of brain injury and subsequent neurodevelopmental outcomes in fetuses and neonates from pregnancies with twin– twin transfusion syndrome. Check out the open-access article for their results: https://bit.ly/48CYDi2

🌐 Today, on World Lymphedema Day, let’s dive deeper into the impact of lymphedema on individuals battling head and neck cancer. Head and neck lymphedema can cause not only physical discomfort but also emotional and psychological challenges, as it may alter one’s appearance and self-confidence. From difficulty eating and speaking to managing daily activities, the burden can be immense. That’s why collaboration with a trained clinician, such as a certified lymphedema therapist, is crucial for comprehensive care and support. A CLT can offer complete decongestive therapy which can significantly improve the condition. Stay tuned through the month of March to learn more! #WorldLymphedemaDay #LymphedemaAwareness #marchislymphedemaawarenessmonth #ptotslp #slp #medicalspeechpathology #HeadAndNeckCancerAwareness 💪🏼💙

Announcing a game changer for patients with mild Traumatic Brain Injury (mTBI) ‼ 📢 VIDAS® TBI (GFAP, UCH-L1)   VIDAS® TBI (GFAP, UCH-L1) safely rules out intracranial lesions (ICL) by simultaneously testing with a combination of biomarkers released in the hours after a #brain trauma.  Its broad window of up to 12 hours covers a wide adult mTBI patient population. Current mTBI patient workup can be subjective and time-consuming. Clinicians typically use CT-scans to rule out ICL.  VIDAS® TBI (GFAP, UCH-L1) raises the standard of care by objectively determining if a CT-scan is needed or not.  🚑 Find out how you can save time & resources while gaining confidence for mTBI patient workup with VIDAS® TBI (GFAP, UCH-L1).  👉 https://lnkd.in/d6UTNFsZ #WorldHeadInjuryAwarenessDay